Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Harun M Patel

Showing results (1-10 of 64) with videos related to

Pageof 7
Sort By:
European Journal of Medicinal Chemistry|December 26, 2024
From challenges to solutions: A review of fourth-generation EGFR tyrosine kinase inhibitors to overcome the C797S triple mutation in non-small cell lung cancerIqrar Ahmad, Harun M Patel
Drug Development Research|December 26, 2024
Orthoallosteric EGFR-TKIs: A New Paradigm in NSCLC Treatment Strategy Targeting the C797S MutationIqrar Ahmad, Harun M Patel
Journal of Cellular Biochemistry|September 20, 2024
Repurposing Non-Nucleosidic Reverse Transcriptase Inhibitors (NNRTIs) to Overcome EGFR T790M-Mediated Acquired Resistance in Non-Small Cell Lung CancerIqrar Ahmad, Harun M Patel
Journal of Basic and Clinical Pharmacy|May 15, 2014
3d QSAR studies on a series of quinazoline derrivatives as tyrosine kinase (egfr) inhibitor: the k-nearest neighbor molecular field analysis approachMalleshappa N Noolvi, Harun M Patel
European Journal of Medicinal Chemistry|December 16, 2024
Catalytic Lysine745 targeting strategy in fourth-generation EGFR tyrosine kinase inhibitors to address C797S mutation resistanceBhatu R Patil, Harun M Patel
Expert Opinion on Therapeutic Patents|July 16, 2025
Overcoming triple mutant EGFR-tyrosine kinase barriers in the therapeutics of non-small cell lung cancer: a patent review on fourth-generation inhibitors (2017-2024)Narendra R Nagpure, Harun M Patel
Chemistry & Biodiversity|May 30, 2020
Exploring MDR-TB Inhibitory Potential of 4-Aminoquinazolines as Mycobacterium tuberculosis N-Acetylglucosamine-1-Phosphate Uridyltransferase (GlmU<sup>MTB</sup> ) InhibitorsHarun M Patel, Mahesh Palkar, Rajshekhar Karpoormath
Medicinal Chemistry (Shariqah (United Arab Emirates))|April 14, 2011
A comparative QSAR analysis of quinazoline analogues as tyrosine kinase (erbB-2) inhibitorsMalleshappa N Noolvi, Harun M Patel, Varun Bhardwaj
Medicinal Chemistry (Shariqah (United Arab Emirates))|April 26, 2012
A QSAR analysis of 2-phenoxy-N-substituted acetamide analogues as hypoxia-inducible factor-1(HIF-1) inhibitors: a rational approach to anticancer drug designMalleshappa N Noolvi, Harun M Patel, Sarita Kamboj
The Indian Journal of Tuberculosis|June 27, 2022
Recent updates in natural terpenoids as potential anti-mycobacterial agentsVilas R Jagatap, Iqrar Ahmad, Harun M Patel
Pageof 7

Showing results (1-10 of 64) with videos related to

Sort By:
Pageof 7
European Journal of Medicinal Chemistry|December 26, 2024
From challenges to solutions: A review of fourth-generation EGFR tyrosine kinase inhibitors to overcome the C797S triple mutation in non-small cell lung cancerIqrar Ahmad, Harun M Patel
Drug Development Research|December 26, 2024
Orthoallosteric EGFR-TKIs: A New Paradigm in NSCLC Treatment Strategy Targeting the C797S MutationIqrar Ahmad, Harun M Patel
Journal of Cellular Biochemistry|September 20, 2024
Repurposing Non-Nucleosidic Reverse Transcriptase Inhibitors (NNRTIs) to Overcome EGFR T790M-Mediated Acquired Resistance in Non-Small Cell Lung CancerIqrar Ahmad, Harun M Patel
Journal of Basic and Clinical Pharmacy|May 15, 2014
3d QSAR studies on a series of quinazoline derrivatives as tyrosine kinase (egfr) inhibitor: the k-nearest neighbor molecular field analysis approachMalleshappa N Noolvi, Harun M Patel
European Journal of Medicinal Chemistry|December 16, 2024
Catalytic Lysine745 targeting strategy in fourth-generation EGFR tyrosine kinase inhibitors to address C797S mutation resistanceBhatu R Patil, Harun M Patel
Expert Opinion on Therapeutic Patents|July 16, 2025
Overcoming triple mutant EGFR-tyrosine kinase barriers in the therapeutics of non-small cell lung cancer: a patent review on fourth-generation inhibitors (2017-2024)Narendra R Nagpure, Harun M Patel
Chemistry & Biodiversity|May 30, 2020
Exploring MDR-TB Inhibitory Potential of 4-Aminoquinazolines as Mycobacterium tuberculosis N-Acetylglucosamine-1-Phosphate Uridyltransferase (GlmU<sup>MTB</sup> ) InhibitorsHarun M Patel, Mahesh Palkar, Rajshekhar Karpoormath
Medicinal Chemistry (Shariqah (United Arab Emirates))|April 14, 2011
A comparative QSAR analysis of quinazoline analogues as tyrosine kinase (erbB-2) inhibitorsMalleshappa N Noolvi, Harun M Patel, Varun Bhardwaj
Medicinal Chemistry (Shariqah (United Arab Emirates))|April 26, 2012
A QSAR analysis of 2-phenoxy-N-substituted acetamide analogues as hypoxia-inducible factor-1(HIF-1) inhibitors: a rational approach to anticancer drug designMalleshappa N Noolvi, Harun M Patel, Sarita Kamboj
The Indian Journal of Tuberculosis|June 27, 2022
Recent updates in natural terpenoids as potential anti-mycobacterial agentsVilas R Jagatap, Iqrar Ahmad, Harun M Patel
Pageof 7